| Literature DB >> 33079039 |
Satoshi Nakano, Takao Fujisawa, Yutaka Ito, Bin Chang, Yasufumi Matsumura, Masaki Yamamoto, Shigeru Suga, Makoto Ohnishi, Miki Nagao.
Abstract
To prevent invasive pneumococcal disease (IPD), pneumococcal conjugate vaccines (PCVs) have been implemented in many countries; however, many cases of IPD still occur and can be attributable to nonvaccine serotypes of Streptococcus pneumoniae. In Japan, the number of IPD cases attributable to serotype 12F increased from 4.4% in 2015 to 24.6% in 2017 after 13-valent PCV was introduced. To clarify the associated genetic characteristics, we conducted whole-genome sequencing of 75 serotype 12F isolates. We identified 2 sequence types (STs) among the isolates: ST4846, which was the major type, and ST6945. Bayesian analysis suggested that these types diverged in »1942. Among serotype 12F-ST4846, we identified a major cluster, PC-JP12F, whose time of most recent common ancestor was estimated to be »2012. A phylogeographic analysis demonstrated that PC-JP12F isolates spread from the Kanto region, the most populated region in Japan, to other local regions.Entities:
Keywords: 12F; 13-valent pneumococcal conjugate vaccine; Japan; PCV13; ST4846; Streptococcus pneumoniae; Tn6002; bacteria; invasive pneumococcal disease; whole-genome sequence
Mesh:
Substances:
Year: 2020 PMID: 33079039 PMCID: PMC7588537 DOI: 10.3201/eid2611.200087
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Antimicrobial susceptibilities of Streptococcus pneumoniae serotype 12F isolates recovered in Japan, 2017*
| Sequence type | No. isolates | MIC, μg/mL | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Penicillin | Cefotaxime | Meropenem | Erythromycin | Levofloxacin | ||||||||||||
| 0.12 | 0.25 | 0.12 | 0.25 | >128 | 0.5 | 1 | ||||||||||
| 4846 | 59 | 16 | 42 | 1 | 54 | 3 | 2 | 59 | 0 | 59 | 4 | 55 | ||||
| 6945 | 16 | 15 | 1 | 0 | 16 | 0 | 0 | 16 | 3 | 13 | 0 | 16 | ||||
*Susceptibility categories were based on Clinical and Laboratory Standard 2015 antimicrobial susceptibility testing standards for S. pneumoniae (). If categories for meningitis are available, they are shown. The standards are penicillin <0.06 susceptible, >0.12 resistant; cefotaxime <0.5 susceptible, 1.0 intermediate, >2 resistant; meropenem <0.25 susceptible, 0.5 intermediate, >1.0 resistant; erythromycin <0.25 susceptible, 0.5 intermediate, >1.0 resistant; levofloxacin <2.0 susceptible, 4.0 intermediate, >8.0 resistant.
Figure 1Recombination-free maximum-likelihood tree of Streptococcus pneumoniae serotype 12F-CC4846 isolates in Japan, created by using Gubbins (). Two clusters were generated: 1 comprised only sequence type (ST) 4846 isolates and the other comprised only ST6945 isolates. All isolates had pbp1a-13. The pbp2x type “others” included pbp2x-JP23, pbp2x-JP58, and pbp2x-JP59. The geographic locations of the described regions in this figure are shown in the Appendix. The numbers on the branches indicate bootstrap values. SNP, single-nucleotide polymorphism; ST, sequence type.
Figure 2Maximum-clade credibility tree of Streptococcus pneumoniae sequence type (ST) 4846 clade isolates. The times of the most recent common ancestor are shown on the tree with 95% highest posterior density. This clade appeared to diversify in »2005, and the tree included 1 major clade, the PC-JP12F clade (pink shading), whose time of most recent common ancestor was »2012.0.
Figure 3Bayesian phylogeography of Streptococcus pneumoniae serotype 12F isolates in the PC-JP12F clade between 6 discrete regions in Japan after the PC-JP12F clade arose. BFs indicate the transmission support; consistent with convention, support was defined as BF>3. Arrows indicate transmission direction. BF, Bayes factors.